REIMAGINE 1: Placebo-Controlled Phase 3 Data on CagriSema in Early Type 2 Diabetes

This blog covered REIMAGINE 2 earlier this month — a head-to-head trial comparing the cagrilintide-semaglutide combination (CagriSema) against its individual components as an add-on to metformin. REIMAGINE 1, published in the same Lancet Diabetes & Endocrinology issue, asks a more basic question first: does the combination beat placebo at all, in people who haven’t yet started background glucose-lowering therapy. It’s a companion trial rather than a follow-up, and the placebo-controlled design gives a cleaner read on the compound’s baseline effect size before comparator trials layer on more variables.

Trial design, briefly

REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study run across 42 sites in six countries, enrolling adults with type 2 diabetes inadequately controlled by diet and exercise alone — a treatment-naive population distinct from the metformin-background cohort in REIMAGINE 2. Of 294 people screened, 189 were randomly assigned (2:1:2:1) to once-weekly subcutaneous cagrilintide-semaglutide at matched 2.4 mg doses, cagrilintide-semaglutide at matched 1.0 mg doses, or one of two dose-matched placebo arms, for 40 weeks. Baseline mean HbA1c was 7.8% and mean BMI was 35.2 kg/m². The primary endpoint was change in HbA1c from baseline to week 40, with bodyweight change as a prespecified secondary endpoint. The trial is registered at ClinicalTrials.gov (NCT06323174) and is complete.

What the trial found

Both combination doses separated clearly from placebo. Estimated mean HbA1c change at week 40 was -1.8 percentage points with the 2.4 mg combination and -1.5 percentage points with the 1.0 mg combination, against -0.1 percentage points with placebo — treatment differences of -1.7 and -1.3 percentage points respectively (both p<0.0001). On the secondary bodyweight endpoint, the 2.4 mg arm showed a -13.8% mean relative change versus -1.4% with placebo (treatment difference -12.4 percentage points), and the 1.0 mg arm showed -11.8% versus the same placebo comparator (treatment difference -10.4 percentage points), both also p<0.0001. Adverse events were reported by 79% of participants in the 2.4 mg group, 75% in the 1.0 mg group, and 66% on placebo, with the excess concentrated in mild-to-moderate gastrointestinal events — consistent with the safety pattern already documented for GLP-1 receptor agonists as a drug class.

How this fits alongside REIMAGINE 2

Where REIMAGINE 2 isolated the incremental contribution of the amylin-receptor component (cagrilintide) on top of semaglutide in a metformin-treated population, REIMAGINE 1 establishes the more fundamental comparison: the full combination against placebo, in a population that hasn’t started any background glucose-lowering therapy yet. The two trials are asking different questions of the same investigational compound, and reading them together gives a more complete picture than either alone — REIMAGINE 1 shows CagriSema clearly outperforms no treatment, while REIMAGINE 2 shows the amylin component adds a modest but statistically real increment over semaglutide by itself. Neither trial was designed to answer the other’s question, which is a useful reminder that a single phase 3 result rarely settles a compound’s full clinical picture.

What this means for ongoing research

REIMAGINE 1 adds placebo-controlled evidence to a still-accumulating dataset on fixed-dose amylin/GLP-1 combinations in type 2 diabetes, complementing the bodyweight-focused REDEFINE program and the metformin-comparator REIMAGINE 2 trial. As with all CagriSema data, this describes a controlled 40-week trial in a defined clinical population under close medical supervision — cagrilintide-semaglutide remains an investigational combination, not an FDA-approved product, and the results here are a research finding about population-level averages rather than a guide to individual treatment.

Further reading

• Aroda VR, Buzzetti R, Dalskov SM, et al. “Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.” The Lancet Diabetes & Endocrinology, 2026;14(8):649-661. PubMed: 42251860 · doi.org/10.1016/S2213-8587(26)00126-9